Collegium Pharmaceutical’s (COLL) “Neutral” Rating Reiterated at Piper Sandler

Piper Sandler reissued their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research note issued to investors on Friday morning,Benzinga reports. Piper Sandler currently has a $37.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $36.00.

Several other equities analysts have also issued reports on COLL. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 19th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Needham & Company LLC restated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $28.89 on Friday. The company has a market cap of $928.29 million, a PE ratio of 12.45 and a beta of 0.63. The firm’s 50 day moving average price is $28.10 and its 200-day moving average price is $30.07. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a 52-week low of $23.23 and a 52-week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Activity

In other news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the completion of the sale, the executive vice president now owns 108,137 shares in the company, valued at approximately $3,081,904.50. This represents a 19.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock worth $2,334,994 over the last 90 days. 2.51% of the stock is currently owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. New Age Alpha Advisors LLC purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter worth $40,000. Wealthquest Corp acquired a new stake in Collegium Pharmaceutical during the 1st quarter worth about $62,000. KBC Group NV raised its stake in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares during the last quarter. Virtus Fund Advisers LLC boosted its stake in shares of Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.